Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Glaukos (GKOS)

Glaukos Q4 sales rise 36% to $143.1 million; $112.9 million impairment drives net loss

Mixed Impact 3 of 5 earnings Written later

Glaukos reported record fourth-quarter 2025 net sales of $143.1 million, up 36% from a year earlier, and full-year net sales of $507.4 million, up 32%. A one-time, non-cash impairment charge of $112.9 million tied to the Photrexa to Epioxa transition pushed the fourth-quarter GAAP net loss to $133.7 million, or $2.32 per diluted share, and the company reaffirmed its 2026 net sales guidance of $600 million to $620 million.

Key points

  • Q4 2025 net sales were $143.1 million, up 36% reported and 34% in constant currency, versus $105.5 million in Q4 2024.
  • Q4 2025 GAAP net loss was $133.7 million, or ($2.32) per diluted share, versus a net loss of $33.6 million, or ($0.60), in Q4 2024.
  • Non-GAAP net loss for Q4 2025 was $16.4 million, or ($0.28) per diluted share.
  • The company reaffirmed 2026 net sales guidance of $600 million to $620 million and ended 2025 with about $282.6 million in cash, short-term investments and restricted cash and no debt.

The filing

CompanyGlaukos (GKOS)
Form8-K, current report
Filed with the SECFeb 17, 2026, 4:10 PM ET
Accession number0001104659-26-016410

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:12 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 17, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.